Role of raltegravir in the management of HIV-1 infection

HIV/AIDS - Research and Palliative Care

Volumn 3, Issue , 2011, Pages 81-92

  Okeke, N Lance ^a   Hicks, Charles ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV; Raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ATAZANAVIR; CREATINE KINASE; INTEGRASE; INTEGRASE INHIBITOR; LAMOTRIGINE; METHADONE; MIDAZOLAM; PLACEBO; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIFAMPICIN; VIRUS DNA;

ADVERSE DRUG REACTION; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; DIARRHEA; DNA CLEAVAGE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MICROBIAL ACTIVITY; NAUSEA; NONHUMAN; REVIEW; RHABDOMYOLYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION;

EID: 84896503763     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S13985     Document Type: Review

References (80)

1. World Health Organization (WHO). Global summary of the HIV/AIDS epidemic. http://www.who.int/hiv/data/en, 2009. Accessed December 10, 2010.
2. Isentress (raltegravir) [package insert] Whitehouse Station, NJ: Merck, 2007.
3. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov. 2005;4: 236-248.
4. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol. 2000;74: 11191-11200.
5. Hazuda DJ, Felock PJ, Hastings JC, et al. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol. 1997; 71: 7005-7011.
6. Fesen M, Kohn K, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A. 1993;90: 2399-2403.
7. Pandey K, Grandgenett D. HIV-1 integrase strand transfer inhibitors: novel insights into their mechanism of action. Retrovirology. 2008;2: 11-16.
8. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 2010;85: 101-118.
9. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A. 2002;99: 6661-6666.
10. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287: 646-650.
11. Zhu K Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type-1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol. 2004;78: 5045-5055.
12. Hazuda DJ, Anthony NJ, Gomes RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A. 2004;101: 11233-11238.
13. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51: 5843-5855.
14. Brainard DM, Wenning LA, Stone JA Stone, et al. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol. 1-26 Jan 2011. Epub 2011 Jan 5.
15. Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009;53: 1747-1752.
16. Francisci D, Martinelli L, Weimer LE, et al. HIV-2 infection, end stage renal disease and protease inhibitor intolerance: which salvage regimen? Clin Drug Investig. 2011;31: 345-349.
17. Molto J, Sanz-Moreno J, Valle M, et al. Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end stage renal disease. Antimicrob Agents Chemother. 2010;54: 3047-3048.
18. Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrartions in HIV-1 1 infection. PloS One. 2009;4: e6877.
19. Iwamoto M, Kassahan K, Matthew D, et al. Lack of pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008;48: 209-214.
20. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53: 2852-2856.
21. Iwamoto M, Wenning L, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy adults. Clin Infect Dis. 2008;47: 137-140.
22. Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI and RTV-sparing regimen of atazanavir experimental dose of 300 mg bid plus raltegravir 400 mg bid in treatment naïve HIV-infected patients. [Abstract No. THLBB204] In: programs and abstracts of the 18th International AIDS Conference (Vienna) 2010.
23. Wenning L, Friedman E, Kost J, et al. Lack of significant drug interaction between raltegravir and tenofovir. Antomicrob Agents Chemother. 2008;52: 3253-3258.
24. Iwamoto M, Wenning L, Petry A, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 2008;52: 4338-4343.
25. Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment-experience patients. AIDS. 2010;24: 2581-2593.
26. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res. 2011;63: 249-253.
27. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1 individuals. J Acquir Immune Defic Syndr. 2006;43: 509-515.
28. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46: 125-133.
29. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatmentnaïve patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52: 350-356.
30. Lennox JL, Dejesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet. 2009;374: 796-806.
31. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efafirenz regimens in treatment-naïve HIV-1 infected patients: 96-week efficacy, durability, subgroup, safety and metabolic analysis. J Acquir Immune Defic Syndr. 2010;55: 39-47.
32. Grinstejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment- experienced patients with multdrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369: 1261-1269.
33. Gatell JM, Katlama C, Grinzstejn B, et al. Long term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr. 2010;53: 456-463.
34. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359: 339-354.
35. Steigbigel R, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010;50: 605-612.
36. Cooper DA, Steigbigel R, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359: 355-365.
37. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22: 1382-1383.
38. Dori L, Buonomoni AR, Viscione M, et al. A case of rhabdomyolysis associated with raltegravir use. AIDS. 2010;24: 473-474.
39. Croce F, Vitello P, Pria D, et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Intl J STD AIDS. 2010;21: 783-785.
40. Masia M. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir: a call for caution. J Infect. 2010;61: 189-196.
41. Gerton J, Ohgi S, Olsen M, et al. Effects of mutations in residues near the active site of human immunodeficiency virus type I integrase on specific enzyme-substrate interactions. J Virol. 1998;72: 5046-5055.
42. Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Brazil J Infect Dis. 2010;14: 513-518.
43. Fikkert V, Van Maele B, Vercammen J, et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol. 2003;77: 11459-11470.
44. Fikkert V, Hombrouck A, Van Remoortel B, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004;18: 2019-2028.
45. Fransen S, Gupta S, Danovich R. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009;83: 11440-114446.
46. Reigadas S, Anies G, Maquelier B, et al. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PloS One. 2010;5: e10311.
47. Delelis O, Thierry S, Subra F, et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother. 2010;54: 491-501.
48. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1 infected patients. J Antimicrob Chemother. 2009;63: 795-804.
49. Quercia R, Dam E, Perez-Bercoff D, et al. Selective advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol. 2009;83: 10245-10249.
50. Hu Z, Kuritzkes D. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010;55: 148-155.
51. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54: 389-393.
52. Fransen S, Karmochkine M, Huang W, et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother. 2009;53: 4522-4524.
53. Garrido C, Geretti A, Zahonero N, et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother. 2010;65: 320-326.
54. Codoner F, Pou C, Thielen A, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res. 2010;88: 281-286.
55. Low A, Prada N. Topper M, et al. Natural polymorphisms of human immunodeficiency virus type I integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009;53: 4275-4282.
56. Sliberstein-Ceccherini F, Malet I, Fabeni L, et al. Specific HIV-1 integrase polymorphism change their prevalence in untreated versus antiretroviral-treated HIV-1 infected patients, all naïve to integrase inhibitors. J Antimicrob Chemother. 2010;65: 2305-2318.
57. Goethals O, Clayton R, Van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 selected with elvitegavir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol. 2008;82: 10366-10374.
58. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir/ritonavir-based regimen in stable HIV-infected patients with suppressed viremia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomized controlled trials. Lancet. 2010;375: 396-407.
59. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study group. AIDS. 2010;24: 1697-1707.
60. Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing enfurvitide to raltgravir in HIV-1 patients well controlled on an enfurvitide based regimen: 24 week results of the CHEER study. J Acquir Immune Defic Syndr. 2009;51: 367-373.
61. Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother. 2010;65: 2485-2488.
62. Young B, Vanig T, DeJesus E, et al. A pilot study of abacavir/lamivudine (ABC/3TC) and raltegravir in antiretroviral naïve HIV-1 infected subjects: 48 week results. [Abstract THPE0112] In: program and abstracts of the 18th International AIDS Conference (Vienna) 2010.
63. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ ritonavir combined with tenofovir disoproxil fumarate/ emtricitabine in treatment-naïve HIV-1 infected subjects. Program and abstracts of the XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria Abstract MOAB0101.
64. Taiwo B, Zheng S, Gallien S, et al. Results of a single-arm study of DRV/r +RAL in treatment-naïve HIV-1-infected patients (ACTG A5262). Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Feb 2011; Boston, USA. Paper 551.
65. Neff CP, Ndolo T, Tandon A, et al. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One. 2010;5: e15257.
66. Gandhi R, Zheng Lu, Bosch R, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PloS One. 2010;7: e1000321.
67. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50: 912-919.
68. Buzon MJ, Massanella M, Llibre J, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med. 2010;16: 460-466.
69. Singh IR, Gorzynski JE, Drobysheva D, et al. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PloS One. 2010;5: e9948.
70. Vispo R, Barreiro, Maida I, et al. Simplification from protease inhibitors to once or twice daily raltegravir: the ODIS trial [Abstract No. MOAB0102] In: program and abstracts of the 18th International AIDS Conference (Vienna) 2010.
71. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a Phase III study of the safety and efficacy of once daily vs twice daily RAL in combination cherapy for treatment-naïve HIV-infected patients. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Feb 2011; Boston, USA. Abstract 150LB.
72. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201: 814-822.
73. Eron J, Durant J, Poizot-Martin I, et al. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). Program and abstracts of the XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract MOAB0105.
74. Eron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. Program and abstracts of 18th Conference on Retroviruses and Opportunistic Infections. Feb 2011; Boston, USA. Paper 151LB.
75. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572 a next generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55: 813-821.
76. DHHS Panel-Office of AIDS Research Advisory Council. US Department of Health and Human Services 2009. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoslescentGL. pdf. Accessed December 28, 2010.
77. Nakamura H, Miyazaki N, Hosoya N, et al. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine and boosted darunavir. J Infect Chemother. 2011;17: 105-110.
78. Hanley WD, Wenning LA, Moreau, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53: 2752-2755.
79. Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir (DRV/r) and raltegravir (RAL) in healthy subjects. Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Oct 2008; Washington DC, USA. Abstract A-962.
80. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleotide reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52: 4228-4232.